98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/01.rlu.0000167505.54998.f0 | DOI Listing |
Biomolecules
June 2025
SPOC Proteomics, Inc., 19001 N. Scottsdale Road, Suite 285, Scottsdale, AZ 85255, USA.
Accurate detection of biomolecular interactions is essential in many areas, from the detection of the presence of biomarkers in the clinic to the development of therapeutic drugs and biologics in biopharma to the understanding of various biological processes in basic research. Traditional endpoint approaches can suffer from false-negative results for biomolecular interactions with fast kinetics. By contrast, real-time detection techniques like surface plasmon resonance (SPR) monitor interactions as they form and disassemble, reducing the risk of false-negative results.
View Article and Find Full Text PDFBrain Dev
August 2025
Department of Pediatrics, Kyorin University School of Medicine, Tokyo, Japan.
Background: In some countries, glutaric acidemia type 1 (GA1) is included in newborn screening (NBS) panels using tandem mass spectrometry (MS/MS) analysis of acylcarnitine. However, the low excretor phenotype of glutaric acidemia type 1 (LE-GA1) has been increasingly recognaized and may lead to false-negative NBS results and can be missed by urine organic acid and plasma acylcarnitine profile analyses.
Case: We report a case of LE-GA1 with an atypical imaging course.
Thyroid
July 2025
Paediatric Endocrinology Unit, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B.), Hôpital Universitaire des Enfants Reine Fabiola (HUDERF), Bruxelles, Belgium.
Newborn screening for congenital hypothyroidism (CH) has been implemented in high-income countries since the 1970s to prevent intellectual disability. A delayed thyrotropin (TSH) rise with a normal TSH on the first dry blood spot (DBS) sample, followed by an abnormal TSH on the subsequent DBS, is sometimes observed in preterm newborns. The incidence of permanent CH and the screening process in preterm newborns remain controversial.
View Article and Find Full Text PDFHepatol Commun
June 2025
MASLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California at San Diego, La Jolla, California, USA.
Background: Metabolic dysfunction and alcohol-associated liver disease (MetALD) may increase liver fibrosis progression, but data on screening are scarce. We aimed to assess the performance of noninvasive tests (NITs) for detecting significant fibrosis in individuals with suspected MetALD.
Methods: This is a cross-sectional study of prospectively enrolled adults identified as overweight or obese.
Clin Gastroenterol Hepatol
May 2025
Service d'Hépatologie, AP-HP, Hôpital Beaujon, Clichy-la-Garenne, France; Université de Paris, UMR1149 (CRI), Inserm, Paris, France. Electronic address:
Background & Aims: Screening of patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), who are at high risk for significant (F2F4) or advanced fibrosis (F3F4), is an unmet need. Recently, several pathways have been proposed to screen patients at risk for MASLD and fibrosis. We aimed to compare their performance in a large cohort of outpatients with T2D.
View Article and Find Full Text PDF